Respirology Search
Respirology Respirology

Conference Reports

European Respiratory Society (ERS) International Congress 2019
Madrid
28 September 2019 - 02 October 2019
American Thoracic Society 2019 (ATS 2019) International Conference
Dallas, Texas, US
17 May 2019 - 22 May 2019
European Lung Cancer Congress 2019 (ELCC 2019)
Geneva, Switzerland
10 April 2019 - 13 April 2019
International Association for the Study of Lung Cancer 19th World Conference on Lung Cancer (WCLC 2018)
Toronto
23 September 2018 - 26 September 2018
European Respiratory Society (ERS) International Congress 2018
15 September 2018 - 19 September 2018
American Thoracic Society International Conference 2018 (ATS 2018)
San Diego, California, US
18 May 2018 - 23 May 2018
European Lung Cancer Congress (ELCC) 2018
Geneva
11 April 2018 - 14 April 2018
American Academy of Allergy, Asthma, and Immunology/World Allergy Organization Joint Congress 2018 (AAAAI/WAO 2018)
Orlando, Florida, US
02 March 2018 - 05 March 2018
Congress of Asian Pacific Society of Respirology (APSR 2017)
Sydney
23 November 2017 - 26 November 2017
International Association for the Study of Lung Cancer (IASLC) 18th World Conference on Lung Cancer (WCLC)
Yokohama, Japan
15 October 2017 - 18 October 2017
27th International Congress of the European Respiratory Society (ERS 2017)
Milan, Italy
09 September 2017 - 13 September 2017
Malaysian Thoracic Society Annual Congress 2017
Kuala Lumpur, Malaysia
20 July 2017 - 23 July 2017
European Lung Cancer Conference (ELCC) 2017
Geneva
05 May 2017 - 08 May 2017
Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Respirology - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
ARCHER 1050: Persistent OS benefit with dacomitinib vs gefitinib in EGFR+ advanced NSCLC
Roshini Claire Anthony, 19 Dec 2019

First-line treatment with the epidermal growth factor receptor tyrosine kinase inhibitor (EGFR TKI) dacomitinib demonstrated persistent survival benefit in patients with EGFR-positive advanced non-small cell lung cancer (NSCLC), according to updated results from the phase III ARCHER 1050* trial.
Sequential afatinib, osimertinib in EGFR+ T790M NSCLC confer >2 years chemo-free time
Pearl Toh, 03 Dec 2018
Sequential treatment with afatinib followed by osimertinib enables prolonged chemotherapy-free treatment while sustaining clinical benefit in patients with EGFR-mutation positive (EGFR+) non-small–cell lung cancer (NSCLC) who acquire T790M mutation, according to the real-world retrospective GioTag study presented at ESMO Asia 2018.